Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer
Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer
复制标题
DOI：
10.7150/jca.31182
复制
发表时间：
2019-01-01
影响因子：
3.9
通讯作者：
Yang, Qiong
中科院分区：
文献类型：
--
作者：
Huang, Yuanyuan;Li, Weiyu;Yang, Qiong
背景：炎症可能通过影响肿瘤血管生成而在促进肿瘤生长中发挥重要作用。我们探讨了格拉斯哥预后评分（GPS）的作用，在转移性结直肠癌患者接受一线bevacizumab.Methods：所有连续转移性结直肠癌患者治疗一线化疗加或不加贝伐单抗是合格的。结果：化疗组中GPS为0、1和2的患者中位无进展生存期（PFS）分别为8.67、8.10和8.27个月（P = 0.17）;中位总生存期（OS）分别为24.87、23.30和17.93个月（P = 0.04）。贝伐珠单抗组中位PFS分别为11.83、8.10和6.87个月中位OS分别为30.80、19.47和18.67个月，P = 0.01（P = 0.03）。在GPS为0的整组患者中，接受贝伐珠单抗联合化疗的患者的PFS和OS均优于单纯化疗的患者（PFS 11.83 vs. 8.67个月，p=0.03; OS 30.80 vs. 24.87个月，p=0.04）。贝伐单抗仅在GPS为0的转移性结直肠癌患者中增加了生存优势。
Background: Inflammation might play an important role in promoting cancer growth partly by affecting tumor angiogenesis. We explored the role of Glasgow prognostic score (GPS) in metastatic colorectal cancer patients receiving first-linebevacizumab.Methods: All consecutive metastatic colorectal cancer patients treated with first-line chemotherapy plus or not plus bevacizumab were eligible. Pre-treatment GPS were collected for all cases.Results: In the chemotherapy group for patients with GPS of 0, 1 and 2, median progression-free survival (PFS) was 8.67, 8.10, and 8.27months, respectively (P = 0.17). Median overall survival (OS) was 24.87, 23.30, and 17.93months, respectively (P = 0.04). In the bevacizumab group, median PFS was 11.83, 8.10, and 6.87 months, respectively (P = 0.01), and median OS was 30.80, 19.47, and 18.67 months, respectively (P = 0.03).In whole group patients with a GPS of 0, both PFS and OS were in favor of patients treated with bevacizumab plus chemotherapy compared with who treated with chemotherapy alone (PFS 11.83 vs. 8.67 months, p=0.03; OS 30.80 vs. 24.87 months, p=0.04).Conclusion: GPS of 0 was correlated with good prognosis. Bevacizumab added a survival advantage only in metastatic colorectal cancer patients with a GPS of 0.